No Data
No Data
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
Tibet Rhodiola Pharmaceutical Holding (600211.SH): The company has always maintained an open attitude towards the introduction of new varieties.
Gelonghui, February 10丨Tibet Rhodiola Pharmaceutical Holding (600211.SH) disclosed that the investor relations activity record shows the company maintains an open attitude toward introducing new varieties and is searching for suitable varieties through multiple aspects and channels. The company currently has sufficient cash flow, but it also adopts a cautious approach to the introduction of new varieties, taking into consideration factors such as market prospects, pricing, and future trends.
Tibet Rhodiola Pharmaceutical Holding (600211.SH): The vaccine production line built by the company in Shanghai has been put into operation.
Gelonghui, February 10 Tibet Rhodiola Pharmaceutical Holding (600211.SH) investor relations activity record shows that the vaccine production line constructed in Shanghai has been transferred to fixed assets and will be depreciated according to relevant accounting policies. Currently, the company is using this production line to conduct process optimization research for some projects. In 2023, the company hired a third-party assessment institution to evaluate the equity of Siwei, and the valuation report indicates that the fair value of this equity is 10 million yuan. According to relevant accounting policy regulations, the company will conduct impairment testing on the balance sheet date at the end of the year to determine whether there are signs of impairment for this asset and will determine it based on the testing results.
Tibet Rhodiola Pharmaceutical Holding (600211.SH) plans to distribute 0.262 yuan per share in the third quarter, with the ex-dividend date on January 21.
Tibet Rhodiola Pharmaceutical Holding (600211.SH) announced that the company plans to distribute a cash dividend of 0.2 per share in the third quarter of 2024...
Tibet Rhodiola Pharmaceutical Holding (600211.SH) third quarter profit distribution plan: a dividend of 2.62 yuan for every 10 shares.
Tibet Rhodiola Pharmaceutical Holding (600211.SH) announced the profit distribution plan for the third quarter of 2024: A-shares each...
tibet rhodiola pharmaceutical holding (600211.SH): is currently participating in the application for the continuation of the fourth to fifth batch of national centralized drug procurement agreement expiration varieties by jiangsu alliance.
Gelonghui November 4th, Tibet Rhodiola Pharmaceutical Holding (600211.SH) stated at the performance briefing that the company is currently participating in the application work for the continued procurement of the 4th-5th batch of nationally organized pharmaceutical centralized procurement agreement-expired varieties by the jiangsu alliance. Please pay attention to the official website of the Jiangsu Provincial Medical Security Bureau for specific results.